

New Trends in Management of Advanced Stages of Renal Cell Carcinoma

Essay

**Submitted for Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine**

By

Mary Tharwat Helmy

M.B.B.Ch

Faculty of Medicine, Tanta University

Under Supervision of

Prof. Dr. Manal Moawad Abdel Wahab

Professor of Clinical Oncology and Nuclear Medicine

Faculty of Medicine – Ain Shams University

Prof. Dr. Mohamed Mohamed El.Bassiouny

Assistant Professor of Clinical Oncology and Nuclear Medicine

Faculty of Medicine – Ain Shams University

Dr. Amr Shafik Tawfik

Lecturer of Clinical Oncology and Nuclear Medicine

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2012



Allah

First and above all, I pray thanking you for your great Blessing, giving me the effort to complete and achieve this work.

*I would like to express my deep gratitude, thanks, and respect to our eminent **Prof. Dr. Manal Moawad Abdel Wahab**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University for her enthusiastic support, encouragement valuable scientific advices, I'm so proud to complete this work under her supervision. May God bless her.*

*I would like to express my thanks and admiration to **Prof. Dr. Mohamed Mohamed El.Bassiouny**, Assistant Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for his kind and meticulous supervision, support, help, valuable supervision all through the work.*

*I am extremely grateful to **Dr. Amr Shafik Tawfik**, Lecturer of Clinical Oncology and Nuclear Medicine Faculty of Medicine, Ain Shams University for his kind supervision, encouragement, wonderful support and meticulous revision of this work.*

*I am really honored by the presence of **Prof. Dr. Ehsan El-Ghoneme**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Cairo University, and **Prof. Dr. Tarek Hussein**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine – Ain Shams University.*



Mary Tharwat





Dedication

To the soul of my beloved Dad

To my wonderful Mom

To my amazing Brother and Sister

The most sincere and most beloved



List of Contents

Subject	Page
List of Abbreviations	I
List of Tables	V
List of Figures	VII
Introduction	1
Aim of the Work	4
Review of Literature	
Chapter (1): Surgical Anatomy	5
Chapter (2): Epidemiology Etiology & Risk Factors ...	9
Chapter (3): Molecular Biology of Renal Cell Carcinoma Signaling Pathways for Intervention	14
Chapter (4): Diagnosis	22
Chapter (5): Pathological Subtypes	34
Chapter (6): Staging and Prognosis	48
Chapter (7): Treatment Options of Advanced Stages of RCC	58
A- Surgery	58
B- Chemotherapy	65
C- Radiotherapy	68
D- Immunotherapy and Vaccination	75
E- Targeted Therapy	82
Chapter (8): Toxicities of Targeted Therapy and Management Strategies	110
Summary	123
References	126
Arabic Summary	\

List of Abbreviations

5-FU	5-fluorouracil
5-HT3	5- hydroxytryptamine receptor 3
ACE	Angiotensin converting enzyme
AEs	Adverse events
BEV	Bevacizumab
BHD	Birt-Hogg-Dube
CA IX	Carbonic anhydrase IX
CCBs	Calcium channel blockers
ccRCC	Clear cell renal cell carcinoma
CEUS	Contrast enhanced ultrasound
chRCC	Chromophobe renal cell carcinoma
CR	Complete remission
CSF-1R	Colony stimulating factor
CT	Computerized tomography
CWG	Cytokine Working Group
CXR	Chest X Ray
CYP 450	Cytochrome P450
DFS	Disease free survival
DOX	Doxorubicin
EGFR	Epidermal growth factor receptor
EORTC	European Organization for Research and Treatment of Cancer
EPIC	European prospective investigation into cancer and nutrition
FDA	Food and Drug Administration
FDG-PET/CT	Fluoro-D-glucose positron emission Tomography/Computerized tomography

FGFR	Fibroblast growth factor receptors
FH	Fumarate hydratase
FKBP-12	FK506-binding protein 12
FLK/KDR	Fetal liver kinase/ Kinase insert domain receptor
FLT-3	Fms-like tyrosine kinase receptor-3
GEM	Gemzar
GLUT-1	Glucose transporter 1
HD	High dose
HFSR	Hand foot skin reaction
HGM-CoA reductase	3-hydroxy-3-methyl-glutaryl-CoA reductase
HIF-1a	Hypoxia inducible factor-1 alpha
HLRCC	Hereditary leiomyomata and renal cell carcinoma
HR	Hazard ratio
Hs	Hours
HU	Hounsfield units
I.V.	Intravenous
INF-a	Interferone-alpha
IU	International Unit
Kg	Kilogram
KPS	Karnofsky Performance status
LC	Local control
LDH	Lactate dehydrogenase
LND	Lymph node dissection
LRF	Locoregional failure
MRI	Magnetic resonance imaging
MSKCC	Memorial Sloan-Kettering Cancer Center
mTOR	Mammalian target of rapamycin
mTORC1	Mammalian target of rapamycin complex 1

MTSC	Mucinous tubular and spindle cell carcinoma
NCCN	National Comprehensive cancer network
NWLCN	North west London Cancer Network
ORR	Overall response rate
OS	Overall survival
P53	protein 53
P70 S6K	Phospho-p70 S6 Kinase
PDGF	Platelet derived growth factor
PHD	prolyl hydroxylase domain
PI3K	Phosphoinositide 3- kinase
PIP3	Phosphatidylinositol-triphosphate
PR	Partial remission
pRCC	Papillary renal cell carcinoma
PTEN	Phosphatase and tensin enzyme
pVHL	Von Hippel-Lindau product
RCC	Renal cell carcinoma
RECIST	Response Evaluation Criteria in Solid Tumor
RN	Radical nephrectomy
RR	Relative risk
RT	Radiation therapy
S.C.	Subcutaneous
SD	Stable disease
SEER	Surveillance, Epidemiology and End Results
STAT1	Signal transducer of activated T 1
SUV	Standardized uptake value
SWOG	Southwest Oncology Group
TARGET	Treatment Approaches in Renal Cancer Global Evaluation
TFE3	Translation elongation factor 3

TGF-α	Transforming growth factor-alpha
TKIs	Tyrosin kinase inhibitors
TSH	Thyroid stimulating hormone
TTP	Time to progression
UCAs	Ultrasonographic contrast agents
US	Ultrasound
VEGF	Vascular endothelial growth factor
VEGFR-1	Vascular endothelial growth factor-1
VHL	Von Hippel-Lindau
Vs.	Versus
WHO	World health organization

List of Tables

Table No.	Title	Page
Table (2.1)	Differential Diagnosis of Hereditary RCC	13
Table (3.1)	Targeted agents and their targets	21
Table (5.1)	2004 WHO Histological classification of RCC	34
Table (6.1)	MSKCC Adverse prognostic factors	56
Table (6.2)	Median survival according to MSKCC Risk groups	56
Table (7.1)	Venous tumor thrombus classification	60
Table (7.2)	Trials evaluating the benefit of cytoreductive nephrectomy in metastatic RCC	62
Table (7.3)	Rational for cytoreductive nephrectomy	63
Table (7.4)	Chemotherapy in Metastatic RCC	67
Table (7.5)	Preoperative Irradiation for RCC	68
Table (7.6)	Postoperative Irradiation for RCC	69
Table (7.7)	Randomized trials of Interferon- α in metastatic RCC	79
Table (7.8)	Vaccine Trials in Metastatic or Advanced RCC	81
Table (7.9)	Summary of the trials	85
Table (7.10)	Best Response Rates of Patients received sorafenib	88

Table No.	Title	Page
Table (7.11)	Ongoing adjuvant targeted therapy trials for high-risk RCC	103
Table (7.12)	Ongoing phase II clinical trials on neoadjuvant targeted therapies	103
Table (7.13)	Ongoing studies of combination regimens	104
Table (7.14)	Ongoing trials of sequential treatment	107
Table (7.15)	National Comprehensive Cancer Network Guidelines recommendations	109
Table (8.1)	Objective response rate, progression-free and overall survival by hypertension (HTN) status	114

List of Figures

Figure No.	Title	Page
Figure (1.1)	Relation of the kidneys to the thorax and vertebral bodies, posterior view	5
Figure (1.2)	Anatomical relationship of the kidneys to the great vessels: Ao, aorta; IVC, inferior vena cava	6
Figure (1.3)	Anatomical relationship of the kidneys to the surrounding organs: C, colon; D, duodenum; E, esophagus; L, liver; P, pancreas; SI, small intestine; Sp, spleen; St, stomach	7
Figure (1.4)	Lymphatic drainage of the kidneys. The dark lymph nodes represent drainage from the left kidney, and white lymph nodes represent drainage from the right	8
Figure (3.1)	VHL gene location	15
Figure (3.2)	In normal kidney, HIF-1a is hydroxylated by PHD proteins and bound by pVHL, catalysing the polyubiquitylation of HIF-1a for degradation via the proteasome	16
Figure (3.3)	Defective pVHL fail to degrade HIF-1a properly in the presence of oxygen. Consequently HIF-1a is overproduced	17
Figure (3.4)	Biologic pathways in RCC	20
Figure (3.5)	mTOR activation supports cancer cell survival	20
Figure (3.6)	Therapeutic targets of anti-angiogenesis therapies for metastatic RCC	21

Figure No.	Title	Page
Figure (4.1)	Imaging pathway in RCC	24
Figure (4.2)	Intratumoral enhancement for assessing tumor response	31
Figure (5.1)	Represents the nephron and the different RCC subtypes in relation to their positions within the nephron and collecting tubule with their characteristic cytogenetic changes	35
Figure (5.2)	Clear cell RCC tumor cells with clear cytoplasm separated by delicate arborizing vasculature	36
Figure (5.3)	Clear cell RCC shows variegated nodular growth (arrows) with areas of hemorrhage and necrosis (arrowheads)	37
Figure (5.4)	Papillary RCC contains areas of hemorrhage, necrosis, and cystic degeneration	38
Figure (5.5)	Papillary RCC type 1 papillae covered by small cells with scanty cytoplasm arranged in a single layer	38
Figure (5.6)	Papillary RCC type 2 tumor cells of high nuclear grade, eosinophilic cytoplasm and pseudostratified nuclei	39
Figure (5.7)	Chromophobe RCC solitary, circumscribed, and not capsulated mass with a homogeneous light brown cut surface	40
Figure (5.8)	Chromophobe RCC large, polygonal cells with prominent cell membrane, irregular nuclei with perinuclear clear halo	40

Figure No.	Title	Page
Figure (5.9)	Multilocular cystic RCC Macroscopic and Microscopic pictures	41
Figure (5.10)	Collecting-duct carcinoma showing infiltrating gray–white tumor	42
Figure (5.11)	Collecting-duct carcinoma infiltrating irregular tubules embedded in fibro-inflammatory stroma	42
Figure (5.12)	Renal medullary carcinoma infiltrative mass arises from the medulla of the kidney	43
Figure (5.13)	Renal medullary carcinoma: solid sheets of cells with abundant cytoplasm, large nuclei, and prominent nucleoli. Intratumoral sickled red blood cells are seen	43
Figure (5.14)	MTSC exhibits bulging shiny mucoid cut surface	44
Figure (5.15)	MTSC composed of tightly packed elongated tubules separated by abundant basophilic extracellular mucin. Aggregates of spindled cells may be present	45
Figure (5.16)	Xp11.2 translocation-associated RCC are generally cortical or subcapsular, well-circumscribed lesions with yellow-tan, variegated cut surfaces	46
Figure (5.17)	Translocation-associated RCC has heterogeneous morphology	46
Figure (7.1)	CT based treatment plan using a combination of four fields	71
Figure (7.2)	Illustration of a preoperative treatment plan for a locally advanced RCC	71

Figure No.	Title	Page
Figure (7.3)	postoperative radiation therapy for a positive margin status post left radical nephrectomy	72
Figure (7.4)	HR for PFS among Subgroups of Patients received sorafenib	88
Figure (7.5)	Kaplan-Meier PFS probability curves for patients receiving BEV+IFN-a patients receiving IFN-a monotherapy	90
Figure (7.6)	Kaplan–Meier Estimates of OS for INF-a group, the temsirolimus group, and the combination-therapy	92
Figure (7.7)	Kaplan-Meier estimates of PFS of Everolimus vs. Placebo	94
Figure (7.8)	PFS with subgroup analysis in patients receiving Everolimus vs. Placebo	95
Figure (7.9)	Kaplan-Meier survival curves of PFS in overall study population for Pazopanib vs. Placebo	96
Figure (7.10)	Subgroup analyses of PFS for patients treated with Pazopanib vs. Placebo	97
Figure (7.11)	OS of adjuvant therapies versus no therapy	102

Introduction

Each year In Europe, approximately 40,000 patients are diagnosed with Renal cell carcinoma (RCC), leading to 20,000 deaths (*Patard et al., 2011*). Although it is the tenth most common malignancy in Europe it accounts for only 2–3% of cancers (*Escudier et al., 2012*). With newer therapies, the median survival period of patients with advanced RCC is about 26 months (*Banumathy and Cairns, 2010*).

The incidence of RCC is increasing at around 2% per year, this had been attributed to increased detection due to the wide spread of imaging modalities (*Wood and Brown, 2012*).

Renal cell carcinoma accounts for approximately 90% of renal malignancies. According to the World Health Organization, there are three major histological RCC types; clear cell renal cell carcinoma (ccRCC) (75%), papillary renal cell carcinoma (pRCC) (10–15%), and chromophobe renal cell carcinoma (chRCC) (5%). pRCC can further be divided into two different subtypes, type 1 and type 2 (*Ljungberg et al., 2010*).

Immunohistologic and ultrastructural analysis have suggested that the proximal renal tubular epithelium is the tissue of origin of most renal tumors. Renal tumors tend to be spherical, but may vary widely in size. The average diameter is